Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Agarwal on Remaining Questions With Renal Cell Carcinoma

November 14th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.

Expert Discusses Degarelix and Other Developments in Prostate Cancer

November 14th 2017

Guru P. Sonpavde, MD, discusses degarelix, androgen-deprivation therapy, and ongoing trials with immunotherapy that are crucial to advancing the treatment of patients with prostate cancer.

Pal Shares Insight on Abundance of Options in GU Malignancies

November 14th 2017

Sumanta K. Pal, MD, discusses advancements in prostate cancer, bladder cancer, and promising results in kidney cancer.

Dr. Grivas on Combining Chemotherapy and Immunotherapy in Bladder Cancer

November 14th 2017

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses combining chemotherapy and immunotherapy as a treatment approach for patients with bladder cancer.

NKTR-214/Nivolumab Combination Shows Promise in Early Study

November 12th 2017

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

IDO Plus PD-1 Inhibitor Combo Sparks Responses in Bladder and Cervical Cancers

November 12th 2017

The combination of nivolumab and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers.

Dr. Luke on Combining an IDO Inhibitor With Nivolumab in Advanced Cancers

November 12th 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses a study evaluating the IDO1 inhibitor BMS-986205 as a monotherapy and in combination with nivolumab in patients with advanced cancers.

Dr. Uzzo on Biomarker Development for RCC

November 10th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).

Dr. Hope on the Future of Imaging for Biochemical Recurrent Prostate Cancer

November 10th 2017

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco (UCSF), discusses the future of imaging for biochemical recurrent prostate cancer.

Dr. Inman on Biomarkers for Immunotherapy in Bladder Cancer

November 10th 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

Checkpoint Inhibitors Herald a New Era for Treating Urothelial Cancer

November 7th 2017

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.

Immunotherapy Continues to Impress in GU Malignancies

November 7th 2017

Andrea Apolo, MD, discusses the combination of cabozantinib plus nivolumab and ipilimumab, as well as the latest data on avelumab in urothelial carcinoma.

Nivolumab Sustains Survival Benefit in RCC at 3 Years

November 7th 2017

Nivolumab reduced the risk of death by 26% compared with everolimus in patients with previously treated advanced renal cell carcinoma.

NICE Recommends Frontline Atezolizumab for Advanced Urothelial Cancer

November 2nd 2017

The UK’s National Institute for Health and Care Excellence is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.

Dr. Armstrong Discusses Hereditary Prostate Cancer

November 1st 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

Dr. Geynisman on Patient Preferences for Treatment of RCC

November 1st 2017

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

Dr. Friedlander on Checkpoint Inhibitors in Second-Line Bladder Cancer Treatment

October 31st 2017

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in second-line bladder cancer treatment.

Research Underway to Cure Locally Advanced Urothelial Carcinoma

October 31st 2017

Elizabeth Plimack, MD, discusses the management of locally advanced urothelial carcinoma and the ongoing trials that are investigating treatments for this patient population.

Dr. Zibelman on Combinations of Immunotherapy for RCC

October 30th 2017

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy combinations in the treatment of patients with renal cell carcinoma (RCC).

Improved Patient Selection Needed to Optimize Expanding Options in Bladder Cancer

October 27th 2017

Jean Hoffman-Censits, MD, discusses ever-changing bladder cancer field, ongoing combination trials that are showing early promise, and the unmet need of patient selection for novel therapies.